The Clinical Research Review Committee (CRC) of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is responsible for reviewing the scientific merit, priorities, and progress of the clinical protocol research of the center. Committee approval is required prior to opening a protocol in the Cancer Center. The committee also has the authority to close protocols that do not demonstrate adequate scientific progress. Over the past five years, the average number of protocols reviewed per year for scientific merit was 115 protocols. These numbers fluctuate year to year with the lowest being in 2001 (92 protocols) due to the Office of Human Research Protection (CHRP) shutdown. In 2004, 135 studies were reviewed for scientific merit. On average, in 2004 each week the committee reviewed 3 new, never-reviewed studies, 1 resubmitted study with CRC recommended changes, and 1 study for annual progress and performance. In 2004, a new CRC Prereview Committee (preCRC) was formed. The purpose of the CRC Prereview Committee is to facilitate the protocol approval process by providing investigators with early feedback on the quality and completeness of their protocols prior to CRC. In addition, the preCRC focuses on ensuring resources are available to support the trial (e.g., nursing, pharmacy, Specimen Accessioning Core). Having the new committee better allows the CRC to focus on the scientific merit, scientific priorities and progress of the research in the Center. Implementation of the preCRC has made the CRC review more efficient and improves research staff efficiency and data quality when the study opens.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
United States
Zip Code
Popovic, Aleksandra; Jaffee, Elizabeth M; Zaidi, Neeha (2018) Emerging strategies for combination checkpoint modulators in cancer immunotherapy. J Clin Invest 128:3209-3218
Peprah, Sally; Curreiro, Frank C; Hayes, Jennifer H et al. (2018) A spatiotemporal analysis of invasive cervical cancer incidence in the state of Maryland between 2003 and 2012. Cancer Causes Control 29:445-453
Springer, Simeon U; Chen, Chung-Hsin; Rodriguez Pena, Maria Del Carmen et al. (2018) Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. Elife 7:
Handy, Catherine E; Antonarakis, Emmanuel S (2018) Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. Future Oncol 14:907-917
Danilova, Ludmila; Anagnostou, Valsamo; Caushi, Justina X et al. (2018) The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity. Cancer Immunol Res 6:888-899
Dean, Lorraine T; Schmitz, Kathryn H; Frick, Kevin D et al. (2018) Consumer credit as a novel marker for economic burden and health after cancer in a diverse population of breast cancer survivors in the USA. J Cancer Surviv 12:306-315
Zhang, Jiajia; Wolfgang, Christopher L; Zheng, Lei (2018) Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer. Cancers (Basel) 10:
Leadem, Benjamin R; Kagiampakis, Ioannis; Wilson, Catherine et al. (2018) A KDM5 Inhibitor Increases Global H3K4 Trimethylation Occupancy and Enhances the Biological Efficacy of 5-Aza-2'-Deoxycytidine. Cancer Res 78:1127-1139
Bharti, Santosh K; Mironchik, Yelena; Wildes, Flonne et al. (2018) Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. Oncotarget 9:15326-15339
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2

Showing the most recent 10 out of 2393 publications